DrugPatentWatch Database Preview

GILEAD SCIENCES INC Company Profile

GILEAD SCIENCES INC has seventeen approved drugs.

There are seventy US patents protecting GILEAD SCIENCES INC drugs.

There are one thousand six hundred and thirty-seven patent family members on GILEAD SCIENCES INC drugs in sixty-eight countries and one hundred and eighty-five supplementary protection certificates in sixteen countries.

International Patents:	1637
US Patents:	70
Tradenames:	16
Ingredients:	16
NDAs:	17
Drug Master File Entries:	7
Patent Litigation for GILEAD SCIENCES INC:	See patent lawsuits for GILEAD SCIENCES INC

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Gilead Sciences Inc	VOSEVI	sofosbuvir; velpatasvir; voxilaprevir	TABLET;ORAL	209195-001	Jul 18, 2017		RX	Yes	Yes	9,284,342	➤ Sign Up	Y	Y		➤ Sign Up
Gilead Sciences Inc	BIKTARVY	bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	210251-001	Feb 7, 2018		RX	Yes	Yes	7,390,791	➤ Sign Up	Y	Y		➤ Sign Up
Gilead Sciences Inc	STRIBILD	cobicistat; elvitegravir; emtricitabine; tenofovir disoproxil fumarate	TABLET;ORAL	203100-001	Aug 27, 2012		RX	Yes	Yes	9,457,036	➤ Sign Up	Y			➤ Sign Up
Gilead Sciences Inc	VIREAD	tenofovir disoproxil fumarate	TABLET;ORAL	021356-001	Oct 26, 2001	AB	RX	Yes	Yes	6,043,230*PED	➤ Sign Up				➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Gilead Sciences Inc	COMPLERA	emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate	TABLET;ORAL	202123-001	Aug 10, 2011	5,914,331*PED	➤ Sign Up
Gilead Sciences Inc	VIREAD	tenofovir disoproxil fumarate	TABLET;ORAL	021356-003	Jan 18, 2012	5,922,695*PED	➤ Sign Up
Gilead Sciences Inc	STRIBILD	cobicistat; elvitegravir; emtricitabine; tenofovir disoproxil fumarate	TABLET;ORAL	203100-001	Aug 27, 2012	5,935,946*PED	➤ Sign Up
Gilead Sciences Inc	VIREAD	tenofovir disoproxil fumarate	TABLET;ORAL	021356-001	Oct 26, 2001	6,057,305	➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Tablets	300 mg	➤ Subscribe	2010-01-26
➤ Subscribe	Tablets	200 mg/25 mg/300 mg	➤ Subscribe	2015-05-20
➤ Subscribe	Tablets	150 mg	➤ Subscribe	2015-12-09
➤ Subscribe	Tablets	150 mg, 200 mg, and 250 mg	➤ Subscribe	2012-05-17
➤ Subscribe	Tablets	150 mg, 150 mg, 200 mg, 300 mg	➤ Subscribe	2018-10-04

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
90017-1	Sweden	➤ Sign Up	PRODUCT NAME: RILPIVIRIN OCH FARMACEUTISKT GODTAGBARA ADDITIONSSALTER DAERAV, INBEGRIPET VAETEKLORSYRASALTET AV RILPIVIRIN; REG. NO/DATE: EU/1/11/736/001 20111128
2015000088	Germany	➤ Sign Up	PRODUCT NAME: KOMBINATION VON RILPIVIRIN ODER EINER THERAPEUTISCH AEQUIVALENTEN FORM DAVON, DIE DURCH DAS GRUNDPATENT GESCHUETZT IST, WIE Z.B EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ VON RILPIVIRIN, EINSCHLIESSLICH DES HYDROCHLORIDSALZES VON RILPIVIRIN, TENOFOVIR, INSBESONDERE TENOFOVIRDISOPROXILFUMARAT, UND EMTRICITABIN; REGISTRATION NO/DATE: EU/1/11/737/001-002 20111128
90060-8	Sweden	➤ Sign Up	PRODUCT NAME: COBICISTAT OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
C0078	France	➤ Sign Up	PRODUCT NAME: COBICISTAT OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE COBICISTAT; REGISTRATION NO/DATE: EU/1/13/830/001-002 20130527
Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.